Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: Relationship with suppression of circulating TGF-Β1

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 3, 2010, Pages 360-368

  Kim, S G ^a   Kim, Y M ^a   Choi, Y H ^a,b   Lee, M G ^a   Choi, J Y ^c   Han, J Y ^c   Cho, S H ^c   Jang, J W ^c   Um, S H ^d   Chon, C Y ^e   Lee, D H ^f   Jang, J J ^g   Yu, E S ^h   Lee, Y S ^c  

^a Seoul National University   (South Korea)

^b Dongguk University   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Korea University Ansan Hospital   (South Korea)

^e Yonsei University   (South Korea)

^f Hanyang University College of Medicine   (South Korea)

^g Seoul National University Hospital   (South Korea)

^h Asan Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

[7 METHYL 6,8 BIS(METHYLTHIO)H PYRROLO[1,2 A]PYRAZINE]; DRUG METABOLITE; OLTIPRAZ; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ANOREXIA; APPENDICITIS; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; BULIMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; FLANK PAIN; HEADACHE; HEMATURIA; HEPATIC ENCEPHALOPATHY; HUMAN; HYPESTHESIA; HYPOTENSION; INDIGESTION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TUMOR; MAJOR CLINICAL STUDY; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SHOULDER IMPINGEMENT SYNDROME; SIDE EFFECT; SKIN DISCOLORATION; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PYRAZINES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77955920049     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.89     Document Type: Article

References (42)

1. DeBakey, S.F., Stinson, F.S., Grant, B.F. & Dufour, M.C. Liver cirrhosis mortality in the United states, 1970-1993. surveillance Report no.41 (National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, 1996).
2. Yoon, Y., Yi, H., Grant, B.F. & Dufour, M.C. Liver cirrhosis mortality in the United states, 1970-1998. surveillance Report no.57 (National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, 2001).
3. Kakizoe, T. Cancer Statistics in Japan 1999 (Foundation for promotion of Cancer Research, tokyo, 1999).
4. Yao, F.Y., Terrault, N.A., Freise, C., Maslow, L. & Bass, N.M. Lamivudine treatment is benefcial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 34, 411-416 (2001).
5. Dienstag, J.L. et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124, 105-117 (2003).
6. Friedman, S.L. The cellular basis of hepatic fbrosis\mechanisms and treatment strategies. N. Engl. J. Med. 328, 1828-1835 (1993).
7. Gressner, A.M. & Weiskirchen, R. Modern pathogenetic concepts of liver fbrosis suggest stellate cells and tGF-beta as major players and therapeutic targets. J. Cell. Mol. Med. 10, 76-99 (2006).
8. Qi, Z., Atsuchi, N., Ooshima, A., Takeshita, A. & Ueno, H. Blockade of type beta transforming growth factor signaling prevents liver fbrosis and dysfunction in the rat. Proc. Natl. Acad. Sci. USA 96, 2345-2349 (1999).
9. Petrides, A.S., Vogt, C., Schulze-Berge, D., Matthews, D. & Strohmeyer, G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 19, 616-627 (1994).
10. Dixon, J.B., Bhathal, P.S. & O'Brien, P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fbrosis in the severely obese. Gastroenterology 121, 91-100 (2001).
11. O'Dwyer, P.J. et al. Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. J. Clin. Invest. 98, 1210-1217 (1996).
12. Benson, A.B. 3rd et al. Chronic daily low dose of 4-methyl-5-(2- pyrazinyl)-1, 2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and frst degree female relatives of breast cancer patients. Clin. Cancer Res. 6, 3870-3877 (2000).
13. Wang, J.S. et al. Protective alterations in phase 1 and 2 metabolism of afatoxin B1 by oltipraz in residents of Qidong, people's Republic of China. J. Natl. Cancer Inst. 91, 347-354 (1999).
14. Jacobson, L.P. et al. Oltipraz chemoprevention trial in Qidong, people's Republic of China: study design and clinical outcomes. Cancer Epidemiol. Biomarkers Prev. 6, 257-265 (1997).
15. Benson, A.B. 3rd. Oltipraz: a laboratory and clinical review. J. Cell. Biochem. Suppl. 17F, 278-291 (1993).
16. Gupta, E. et al. Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent. Clin. Cancer Res. 1, 1133-1138 (1995).
17. Kang, K.W. et al. Oltipraz regenerates cirrhotic liver through CCAAt/enhancer binding protein-mediated stellate cell inactivation. FASEB J. 16, 1988-1990 (2002).
18. Kang, K.W., Choi, S.H., Ha, J.R., Kim, C.W. & Kim, S.G. Inhibition of dimethylnitrosamine-induced liver fbrosis by [5-(2-pyrazinyl)-4-methyl-1,2- dithiol-3-thione] (oltipraz) in rats: suppression of transforming growth factor-beta1 and tumor necrosis factor-alpha expression. Chem. Biol. Interact. 139, 61-77 (2002).
19. Bae, E.J., Yang, Y.M., Kim, J.W. & Kim, S.G. Identifcation of a novel class of dithiolethiones that prevent hepatic insulin resistance via the adenosine monophosphate-activated protein kinase-p70 ribosomal s6 kinase-1 pathway. Hepatology 46, 730-739 (2007).
20. Hwahng, S.H., Ki, S.H., Bae, E.J., Kim, H.E. & Kim, S.G. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal s6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology 49, 1913-1925 (2009).
21. Dimitrov, N.V. et al. Oltipraz concentrations in plasma, buccal mucosa cells, and lipids: pharmacological studies. Cancer Epidemiol. Biomarkers Prev. 10, 201-207 (2001).
22. O'Dwyer, P.J., Szarka, C., Brennan, J.M., Laub, P.B. & Gallo, J.M. pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose. Clin. Cancer Res. 6, 4692-4696 (2000).
23. Hasler, J.A. et al. Human cytochromes p450. Mol. Aspects Med. 20, 1137 (1999).
24. Bae, S.K., Lee, S.J., Kim, Y.H., Kim, T. & Lee, M.G. Efects of enzyme inducers and inhibitors on the pharmacokinetics of oltipraz in rats. J. Pharm. Sci. 57, 443-452 (2005).
25. Bieder, A. et al. Comparison of the metabolism of oltipraz in the mouse, rat and monkey and in man. Distribution of the metabolites in each species. Arzneimittelforschung. 33, 1289-1297 (1983).
26. Heusse, D. et al. Disposition of [14C]-oltipraz in animals. pharmacokinetics in mice, rats and monkeys. Comparison of the biotransformation in the infected mouse and in the schistosomes. Arzneimittelforschung 35, 1431-1436 (1985).
27. Bae, S.K. et al. Pharmacokinetic changes of oltipraz after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine. Int. J. Pharm. 275, 227-238 (2004).
28. Bae, S.K. et al. Pharmacokinetics and therapeutic efects of oltipraz after consecutive or intermittent oral administration in rats with liver cirrhosis induced by dimethylnitrosamine. J. Pharm. Sci. 95, 985-997 (2006).
29. Bae, S.K. et al. Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharm. Drug Dispos. 26, 99-115 (2005).
30. Davies, B. & Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093-1095 (1993).
31. Bae, S.K., Kim, J.W., Kim, Y.H., Kim, Y.G., Kim, S.G. & Lee, M.G. Hepatic and intestinal frst-pass efects of oltipraz in rats. Biopharm. Drug Dispos. 26, 129-134 (2005).
32. Dimitrov, N.V., Bennett, J.L., McMillan, J., Perlof, M., Leece, C.M. & Malone, W. Clinical pharmacology studies of oltipraz-a potential chemopreventive agent. Invest. New Drugs 10, 289-298 (1992).
33. Ali, H.M., Homeida, M.M., Sulaiman, S.M. & Bennett, J.L. Diet-controlled blood levels of oltipraz in healthy male subjects. J. Antimicrob. Chemother. 13, 465-470 (1984).
34. Kwon, Y.N., Shin, S.M., Cho, I.J. & Kim, S.G. Oxidized metabolites of oltipraz exert cytoprotective efects against arachidonic acid through AMp-activated protein kinase-dependent cellular antioxidant efect and mitochondrial protection. Drug Metab. Dispos. 37, 1187-1197 (2009).
35. Ko, M.S., Lee, S.J., Kim, J.W., Lim, J.W. & Kim, S.G. Diferential efects of the oxidized metabolites of oltipraz on the activation of CCAAt/enhancer binding protein-beta and NF-E2-related factor-2 for GstA2 gene induction. Drug Metab. Dispos. 34, 1353-1360 (2006)
36. El tayeb, M., Dafalla, A.A., Kardaman, M.W., See, R. & Fenwick, A. Praziquantel and oltipraz: the treatment of schoolchildren infected with Schistosoma mansoni and/or Schistosoma haematobium in Gezira, sudan. Ann. Trop. Med. Parasitol. 82, 53-57 (1988).
37. Benson, A.B. 3rd et al. Phase I study of 5-(2-pyrazinyl)-4-methyl-1,2- dithiole-3-thione (oltipraz, Rp35972) in male patients with previously resected colon polyps and frst degree relatives of breast cancer patients. Proc. Am. Soc. Clin. Oncol. 11, 402 (1992).
38. Flisiak, R., Pytel-Krolczuk, B. & Prokopowicz, D. Circulating transforming growth factor beta(1) as an indicator of hepatic function impairment in liver cirrhosis. Cytokine 12, 677-681 (2000).
39. Kanzler, S. et al. Prediction of progressive liver fbrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J. Viral Hepat. 8, 430-437 (2001).
40. Bedossa, P., peltier, E., Terris, B., Franco, D. & Poynard, T. Transforming growth factor-beta 1 (tGF-beta 1) and tGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 21, 760-766 (1995).
41. Biopharmaceutics Coordinating Committee. Guidance for Industry, Bioanalytical Method Validation (Us Department of Health and Human services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), Rockville, MD, 2001).
42. Gibaldi, M. & Perrier, D. Pharmacokinetics 2nd edn. (Marcel Dekker, New York, 1982).